back to
back to

Program: Saturday (22.10.2022)

08:45 – 10:15

Room: Großer Saal

Seminar Living beyond Lymphoma

  • Lena Specht
  • Flora van Leeuwen
  • 08:45–09:15

    Patient perspective

    • Louise Jennings
    • Jack Richardson
  • 09:15–09:35

    Organisation of HL survivorship care in the UK, ADAPT program

    • Tracy Howe
    • John Radford
  • 09:35–09:55

    Organisation of HL survivorship care in the Netherlands and design of INSIGHT costeffectiveness study

    • Berthe Aleman
  • 09:55–10:15

    Organisation of HL survivorship care in the U.S.

    • Kevin Oeffinger

08:45 – 10:15

Room: Kleiner Saal

Workshop The HL Microenvironment

  • Scott Rodig
  • Andreas Rosenwald
  • 08:45–09:15

    Lessons from the Periphery – Single Cell Analyses of the Circulating Immune Signature in Hodgkin Lymphoma

    • Margaret Shipp
  • 09:15–09:45

    Spatial Proteomic Analyses of the Intact Tumor Microenvironment in Hodgkin Lymphoma – One Cell or Region at a Time

    • Scott Rodig
  • 09:45–10:15

    Microenvironmental Lessons from the NIVAHL Trial

    • Wolfram Klapper

08:45 – 10:15

Room: Ratsstube

Joint EHA-ISHL Symposium

  • Peter Borchmann
  • Martin Dreyling
  • 08:45–09:00

    Introduction to GHSG

    • Peter Borchmann
  • 09:00–09:15

    In memoriam of Ton Hagenbeek

    • Marie Jose Kersten
  • 09:15–09:45

    Future perspectives for prognostication and MRD in cHL

    • Sven Borchmann
  • 09:45–10:15

    EV miRNA in cHL

    • Michiel Pegtel

08:45 – 10:15

Room: Weinkeller

Workshop PET beyond Deauville

  • Sally Barrington
  • Martin Hutchings
  • Carsten Kobe
  • 08:45–09:15

    MTV and Baseline PET biomarkers

    • Sally Barrington
  • 09:15–09:45

    Latest developments in software and PET technology

    • Irene Buvat
    • Carsten Kobe
  • 09:45–10:15

    Imaging response in the context of immunotherapy

    • Philippe Armand
    • Martin Hutchings

08:45 – 10:15

Room: Marsilius Saal

Workshop Innovation for Older Patients

  • Paul J. Bröckelmann
  • Alexander Fosså
  • 08:45–09:05

    Lymphoma Biology and Immunosenescence in Older Patients

    • Alessandra Tucci
  • 09:05–09:25

    Efficacy and Safety of Targeted Drugs in Older HL Patients

    • Ingrid Glimelius
  • 09:25–09:45

    Current and Future Trial Landscape in Older Patients

    • Alexander Fosså
  • 09:45–10:15

    Open Discussion Forum: Adressing Unmet Needs

10:30 – 12:00

Room: Großer Saal

Seminar Radiotherapy: Identifying the Beneficiaries

  • Christian Baues
  • Joachim Yahalom
  • 10:30–11:00

    Indications and current policy for radiotherapy in early and advanced stage HL based on GHSG randomized studies

    • Christian Baues
  • 11:00–11:30

    Who benefits from adding radiotherapy even if PET-negative based on the RAPID study data

    • David Cutter
  • 11:30–12:00

    The experience of incorporating RT into CAR-T cell salvage programs- Does it apply to HL patients?

    • Brandon Imber

10:30 – 12:00

Room: Marsilius Saal

Seminar Learning from Pediatric HL

  • Jonathan Friedberg
  • Christine Mauz-Körholz
  • 10:30–10:43

    Framing the discussion and key issues in adolescent and young adult Hodgkin Lymphoma

    • Christine Mauz-Körholz
  • 10:43–10:56

    Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma

    • Sharon Castellino
  • 10:56–11:13

    SEARCH for CAYAHL initiative

    • Jamie Flerlage
  • 11:13–11:26

    Importance of QoL and PROs in long-term follow-up of HL

    • Susan Parsons
  • 11:26–11:43

    Development and execution of S1826 trial: North American NCTN pediatric/adult collaboration

    • Jonathan Friedberg
  • 11:43–12:00

    Lessons from European Network for Pediatric Hodgkin Lymphoma

    • Dieter Körholz

10:30 – 12:00

Room: Kleiner Saal

Workshop Bringing Liquid Biopsy to Patients

  • Sven Borchmann
  • Davide Rossi
  • 10:30–10:46

    Liquid Biopsy in Lymphoma: The Swiss Experience

    • Cristina Pirosa
  • 10:46–11:02

    Liquid Biopsy in Lymphoma: The Cologne experience

    • Michel Heger
  • 11:02–11:18

    Integrating Fragmentomics and MRD in Lymphoma

    • Leo Meriranta
  • 11:18–11:26

    Challenges in bringing Liquid Biopsy to Lymphoma patients – Kick-off talk for round table

    • Sven Borchmann
  • 11:26–12:00

    Challenges in bringing Liquid Biopsy to Lymphoma patients – Round table

    • Sally Barrington
    • Bastian von Tresckow

10:30 – 12:00

Room: Weinkeller

Workshop NLPHL

  • Michael Binkley
  • Dennis Eichenauer
  • Sylvia Hartmann
  • 10:30–11:00

    Where belongs NLPHL? Biology and pathology

    • Sylvia Hartmann
  • 11:00–11:30

    Treatment of NLPHL: what evidence is available?

    • Dennis Eichenauer
  • 11:30–12:00

    The GLOW database: a tool to answer open questions in NLPHL

    • Michael Binkley

12:15 – 13:45

Room: Großer Saal

Satellite Symposium (by BeiGene Switzerland GmbH) Opening paths to the next chapters of lymphoma treatmen

  • In memoriam of Saul Rosenberg

    • Ranjana Advani

  • Welcome and Introduction to the topic

    • Peter Borchmann

  • Hodgkin’s lymphoma as a model for immuno-oncologic therapeutic approaches to lymphoma

    • Paul J. Bröckelmann

  • The challenge of the older patient in lymphoma therapy

    • Graham Collins

  • New trends in lymphoma therapy: future role of BTKi / CAR-T / bispecific antibodies

    • Pier Luigi Zinzani

14:00 – 15:30

Room: Großer Saal

Scientific Session Early Stages

  • Marc André
  • Hans Theodor Eich
  • 14:00–14:22

    Standard treatment of early-stage HL

    • John Radford
  • 14:22–14:45

    Individual risk assessment of RT in HL

    • Richard Hoppe
  • 14:45–14:51

    WS Report: NLPHL

    • Michael Binkley
    • Dennis Eichenauer
    • Sylvia Hartmann
  • 14:51–15:04

    Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies

    • Dennis Eichenauer
  • 15:04–15:17

    Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

    • Andrea Gallamini
  • 15:17–15:30

    Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

    • Rebecca Shakir

16:00 – 17:30

Room: Großer Saal

Satellite Symposium (by Bristol-Myers Squibb) CAR T cell therapy in B Cell NHL: Status quo and future perspectives

  • Peter Borchmann
  • Paula Cramer
  • 16:00–16:30

    Status quo of CAR T cell therapy for r/r DLBCL

    • Peter Borchmann
  • 16:30–17:00

    New perspective for the treatment of r/r CLL

    • Paula Cramer
  • 17:00–17:30

    CAR T – Lessons Learned

    • Christoph Scheid

18:00 – 19:00

Room: Großer Saal

Main Program Opening and Award Ceremony

  • 18:00–18:05

    Welcoming Address

    • Andreas Engert
  • 18:05–18:20

    Award Ceremony

    • Peter Borchmann
    • Sven Borchmann
    • Paul J. Bröckelmann
    • Dennis Eichenauer
  • 18:20–18:30

    Introduction to the Keynote Lecturer

    • Volker Diehl
  • 18:30–19:00

    Keynote Lecture

    • Uğur Şahin

19:00

Room: Kleiner Saal

Main Program Welcome Reception

19:00 – 20:30

Room: Foyer (Ground Floor)

Main Program Poster Session

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.